Pyxant is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients. Under the deal, Pyxant will offer bioanalytical method development, sample analysis and
Based on the review, the FDA has determined that they cannot approve the new drug application (NDA) in its present form, stating the NDA does have sufficient information
CTSI’s Catalyst Awards program solicits applications from university scientists who wish to move their translational research beyond the bench and into product development. The collaboration marks the first
The drug is approved for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed and who have received at least two prior treatment regimens and
The trial of IMAB027, which is a first-in-class monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6), is being carried out in Germany, Belgium, Russia and Ukraine. Ganymed
The company said that Phase III clinical trials in type 1 and type 2 diabetes will commence soon. Merck senior vice president of Diabetes, Global Human Health Matt
The company already has exclusive rights of Cynviloq from Samyang in the US and the 27 countries of the European Union (EU). Sorrento president and chief executive officer
Under the deal, SynCo will manufacture Advaxis’ novel drug candidate, ADXS-HPV as well as assist them in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance
The company said that ENU is a naturally improved, complete nutritional shake that is flavorful, with 25g of protein per serving and 40% less sugar per ounce compared
BMN 250 is a new fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2). The company has also started IND-enabling studies and intends
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.